• Citer

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer.

par Di Leo, Angelo ;Bleiberg, Harry ;Buyse, Marc
Référence Journal of clinical oncology, 21, 10, page (2045-2047)
Publication Publié, 2003-05

Article révisé par les pairs

• Détails

Titre:	Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer.
Auteur:	Di Leo, Angelo; Bleiberg, Harry; Buyse, Marc
Informations sur la publication:	Journal of clinical oncology, 21, 10, page (2045-2047)
Statut de publication:	Publié, 2003-05
Sujet CREF:	Cancérologie
MeSH keywords:	Breast Neoplasms -- drug therapy -- mortality -- pathology
	Clinical Trials, Phase III as Topic
	Colorectal Neoplasms -- drug therapy -- mortality -- pathology
	Confounding Factors (Epidemiology)
	Humans
	Neoplasm Metastasis
	Survival Analysis
	Treatment Outcome
Note générale:	Letter
	SCOPUS: le.j
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2003.99.089
	info:pii/JCO.2003.99.089
	info:scp/0037674049
	info:pmid/12743164